Literature DB >> 28685501

Pazopanib for second recurrence of osteosarcoma in pediatric patients.

Katsutsugu Umeda1, Itaru Kato1, Satoshi Saida1, Takeshi Okamoto2, Souchi Adachi3.   

Abstract

Entities:  

Keywords:  osteosarcoma; pazopanib; pediatric; recurrence; tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2017        PMID： 28685501     DOI： 10.1111/ped.13307

Source DB:  PubMed          Journal:  Pediatr Int        ISSN： 1328-8067            Impact factor:   1.524


× No keyword cloud information.
  9 in total

1.  Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults.

Authors:  Jessica Bodea; Kenneth J Caldwell; Sara M Federico
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

2.  The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study.

Authors:  Feifei Sun; Suying Lu; Zijun Zhen; Jia Zhu; Juan Wang; Junting Huang; Yu Zhang; Hui Li; Ruiqing Cai; Meiling Liu; Liuhong Wu; Xiaofei Sun; Yizhuo Zhang
Journal:  Cancer Manag Res       Date:  2020-07-22       Impact factor: 3.989

Review 3.  Update on Osteosarcoma.

Authors:  Rebekah Belayneh; Mitchell S Fourman; Sumail Bhogal; Kurt R Weiss
Journal:  Curr Oncol Rep       Date:  2021-04-21       Impact factor: 5.075

4.  Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study.

Authors:  Zhichao Tian; Zhiyuan Gu; Xin Wang; Zhiyong Liu; Weitao Yao; Jiaqiang Wang; Peng Zhang; Qiqing Cai; Hong Ge
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity.

Authors:  Cinzia Zucchini; Maria Cristina Manara; Camilla Cristalli; Marianna Carrabotta; Sara Greco; Rosa Simona Pinca; Cristina Ferrari; Lorena Landuzzi; Michela Pasello; Pier-Luigi Lollini; Marco Gambarotti; Davide Maria Donati; Katia Scotlandi
Journal:  J Exp Clin Cancer Res       Date:  2019-12-26

6.  Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcoma.

Authors:  Christopher E Lietz; Erik T Newman; Andrew D Kelly; David H Xiang; Ziying Zhang; Caroline A Luscko; Santiago A Lozano-Calderon; David H Ebb; Kevin A Raskin; Gregory M Cote; Edwin Choy; G Petur Nielsen; Benjamin Haibe-Kains; Martin J Aryee; Dimitrios Spentzos
Journal:  Commun Biol       Date:  2022-03-08

Review 7.  Tyrosine kinase inhibitors in sarcoma treatment.

Authors:  Anastasios Kyriazoglou; Lydia Evangelia Gkaralea; Ioannis Kotsantis; Maria Anastasiou; Anastasios Pantazopoulos; Maria Prevezanou; Ioannis Chatzidakis; Georgios Kavourakis; Panagiota Economopoulou; Ioanna Fragkandrea Nixon; Amanda Psyrri
Journal:  Oncol Lett       Date:  2022-04-21       Impact factor: 2.967

Review 8.  Origin and Therapies of Osteosarcoma.

Authors:  Brice Moukengue; Morgane Lallier; Louise Marchandet; Marc Baud'huin; Franck Verrecchia; Benjamin Ory; Francois Lamoureux
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

9.  Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.

Authors:  Douglas J Harrison; Jonathan D Gill; Michael E Roth; Wendong Zhang; Beverly Teicher; Stephen Erickson; Greg Gatto; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith; Edward Anders Kolb; Richard Gorlick
Journal:  Pediatr Blood Cancer       Date:  2020-03-24       Impact factor: 3.167
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.